Louis Archambault
Chercheur universitaire
Axe Oncologie
HEJ
G0.440
Québec, QC
Canada G1J 1Z4
Full professor
Department of Physics, Engineering Physics and Optics
Faculty of Science and Engineering
Louis Archambault is a researcher in medical physics. Holding a Ph.D. in Physics from Université Laval, he furthered his expertise with a postdoctoral fellowship at the M. D. Anderson Cancer Center. Joining the Department of Physics, Physical Engineering, and Optics at Université Laval in 2013, he became a full professor in 2023. The core of his research focuses on improving radiotherapy treatments through the development of new tools and the application of data science. He strives to perform accurate mapping of radiation doses used in radiotherapy and to predict the progression of cancer treatments using imaging. His laboratory, named “Clairvoyance,” aptly reflects this ambition for “viewing” radiation doses and predicting the response of treatments.
Louis Archambault is a renowned specialist in optical dosimetry. He has distinguished himself by developing new instruments for the rapid and accurate measurement of radiation doses in radiotherapy, a necessity given the increasing complexity of these treatments. Among his innovations are multipoint and three-dimensional dosimeters using hyperspectral imaging, significant advancements for mapping cutting-edge treatments in radiation oncology. These tools are applicable to all forms of radiotherapy, including proton therapy and ultra-high dose rate radiotherapy, areas of constant evolution.
His laboratory doesn’t stop at these technological innovations. It also embraces data science and artificial intelligence to integrate information from medical imaging (computed tomography, positron emission tomography, magnetic resonance imaging) into support systems for clinical teams in oncology. His work has led to the creation of a predictive system for prostate cancer, relying on an array of clinical data and imaging to determine the most appropriate treatment for a given patient. Furthermore, he has developed an innovative system to determine the optimal achievable dose distribution specific to each patient in radiotherapy, contributing to both improved quality and accelerated treatment planning processes.
In summary, Professor Archambault’s work is crucial for improving the personalization of oncological care, marking a significant advancement in the personalization and efficacy of radiotherapy treatments. These advancements aim to ensure that each patient receives the most effective treatment with the least possible toxicity.
Team
Louis Bernard St-Cyr
Étudiant 3e cycle
HEJ
1401, 18e rueQuébec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67032 +1 418 691-5268 louis-bernard.st-cyr.1@ulaval.ca louis-bernard.st-cyr@crchudequebec.ulaval.ca
Philippe Dionne
Étudiant 3e cycle
HEJ
2250, boulevard Henri BourassaG0.462
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67036 philippe.dionne@crchudequebec.ulaval.ca
Raphaël Brodeur
Étudiant 3e cycle
Mohammed Obaid
Étudiant 2e cycle
HEJ
1401, 18e rueCIC
Québec, QC
Canada G1J 1Z4 9 rue McMahon
Québec, QC
Canada G1R 3S3 +1 418 525-4444 mohammed.obaid.1@ulaval.ca mohammed.obaid@crchudequebec.ulaval.ca
Boby Lessard
Employé
Camille Rochon
Employée
HEJ
1401, 18e rueQuébec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67032 +1 418 691-5268 camille.rochon.1@ulaval.ca
Sajjad Ahmad Khan
Étudiant 3e cycle
Raphaël Brodeur
Étudiant 2e cycle
Audran Poher
Étudiant 3e cycle
HEJ
1401, 18e rueCIC
G0.462
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67036 audran.poher@crchudequebec.ulaval.ca
Nicolas Drouin
Étudiant 2e cycle
Thibault Mathieu Bernelin
Étudiant 3e cycle
Philippe Dionne
Étudiant 2e cycle
HEJ
2250, boulevard Henri BourassaG0.462
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67036 philippe.dionne@crchudequebec.ulaval.ca
Publications
View all-
article Khazaei Z, Pouliot F, Archambault L
Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches
Cancers (Basel) 18 (11), 2026.
-
article de Vries LJM, Borman PTS, Bosma T, Foppen T, Woodings SJ, Côté B, Lambert-Girard S, Therriault-Proulx F, Archambault L, Fast MF
Evaluation of the hyperspectral multicomponent calibration for plastic scintillation dosimetry
Phys Med Biol 71 (11), 2026.
-
article Fabi F, Crook J, Jolicoeur M, Rauth S, Koll W, Tisseveransinghe S, Ebacher A, Niazi T, Duplan D, Bernard AA, Vavassis P, Foster W, Vigneault É and Archambault L, Beaulieu L, Lavallée MC, Lacroix F, Carignan D, Martin AG
Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional no…
Radiother Oncol 221 2026.
Projects
- Expanding the boundaries of scintillation dosimetry with data science, signal processing and innovative design, from 2024-04-01 to 2029-03-31
- Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging, from 2024-09-01 to 2027-08-31
- Bringing three-dimensional dosimetry in the clinic for advanced quality control in radiation therapy, from 2025-01-13 to 2028-06-30
- Dosimétrie par polarimétrie du rayonnement Cherenkov en radiothérapie, from 2025-07-01 to 2027-07-01
- The advent of intelligent real-time dosimetry to optimize image-guided radiotherapy and ensure treatment safety, from 2025-10-01 to 2026-12-31
- Validation clinique de l'Hyperscint MD, from 2023-10-18 to 2024-10-17
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , from 2024-06-17 to 2025-06-16
- 2SHARP:Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer. , from 2024-06-19 to 2025-03-31